Assessing heterogeneity in surrogacy using censored data

Author:

Parast Layla1ORCID,Tian Lu2ORCID,Cai Tianxi3

Affiliation:

1. Department of Statistics and Data Sciences The University of Texas at Austin Austin Texas

2. Department of Biomedical Data Science Stanford University Stanford California

3. Department of Biostatistics Harvard University Cambridge Massachusetts

Abstract

Determining whether a surrogate marker can be used to replace a primary outcome in a clinical study is complex. While many statistical methods have been developed to formally evaluate a surrogate marker, they generally do not provide a way to examine heterogeneity in the utility of a surrogate marker. Similar to treatment effect heterogeneity, where the effect of a treatment varies based on a patient characteristic, heterogeneity in surrogacy means that the strength or utility of the surrogate marker varies based on a patient characteristic. The few methods that have been recently developed to examine such heterogeneity cannot accommodate censored data. Studies with a censored outcome are typically the studies that could most benefit from a surrogate because the follow‐up time is often long. In this paper, we develop a robust nonparametric approach to assess heterogeneity in the utility of a surrogate marker with respect to a baseline variable in a censored time‐to‐event outcome setting. In addition, we propose and evaluate a testing procedure to formally test for heterogeneity at a single time point or across multiple time points simultaneously. Finite sample performance of our estimation and testing procedure are examined in a simulation study. We use our proposed method to investigate the complex relationship between change in fasting plasma glucose, diabetes, and sex hormones using data from the diabetes prevention program study.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Reference46 articles.

1. Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?

2. FDA.Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure.https://www.fda.gov/drugs/development‐resources/table‐surrogate‐endpoints‐were‐basis‐drug‐approval‐or‐licensure2022.

3. Geary.FDA approves Jardiance (empagliflozin) tablets for adults with type 2 diabetes.https://investor.lilly.com/news‐releases/news‐release‐details/fda‐approves‐jardiancer‐empagliflozin‐tablets‐adults‐type‐22014.

4. Statistical validation of intermediate endpoints for chronic diseases

5. ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3